• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PRESSLED

Your Leading News Source

PRESSLED
Your Leading News Source

  • Home
  • BUSINESS
  • MONEY
  • POLITICS
  • REAL ESTATE
  • US
  • Meet the Reporters
  • About/Contact

2020’s Other Tragedy (Gwen Moritz Editor’s Note) | Arkansas Business News

May 23, 2021 by Staff Reporter

We were unable to send the article.

Unless you were personally affected by it, you might not realize that COVID-19 wasn’t the only driver of the national spike in deaths last year. Deaths from opioid overdoses, which were rocking along at give-or-take 4,000 a month, roared to more than 7,200 in May 2020 and remained well above pre-pandemic levels thereafter.

Data is still being collected, but preliminary numbers are leading to estimates of 90,000 overdose deaths last year, maybe more. That’s a nationwide increase of between 25% and 30% over 2019, which was itself a record year after the slight decrease in 2018 that gave some of us false hope.

Arkansas, according to what the Centers for Disease Control & Prevention acknowledges to be incomplete data, saw deaths from drug overdoses (mainly opioids) explode by 39.2% in the federal fiscal year that ended in October 2020. Comparing January through August in 2020 with the first eight months of 2019 was even worse: an increase of 42.3% in Arkansas, according to monthly CDC data crunched by The Commonwealth Fund. Only 10 states saw bigger spikes during those months.

(This isn’t giving me confidence in the popular theory that medical marijuana will help fix the opioid crisis. But the price of marijuana in Arkansas’ closed, heavily regulated industry — $400 an ounce and no insurance coverage — might be a factor, so I’m reserving judgment.)

“The primary driver” of the increase in overdose deaths last year was not prescription painkillers but “synthetic opioids (primarily illicitly manufactured fentanyl),” according to the CDC. But it was the introduction of OxyContin by Purdue Pharma in 1996 that ushered in a new era of addiction by Americans of all socioeconomic classes and created the desperate market for cheap, deadly alternatives.

Last week, I devoted two evenings to HBO’s riveting and deeply disturbing new documentary about the opioid crisis, “The Crime of the Century.” It is the work of Alex Gibney, the documentarian behind “Enron: The Smartest Guys in the Room” and “The Inventor: Out for Blood in Silicon Valley,” the story of Elizabeth Holmes and Theranos, and it has a similar feel.

But instead of just one executive driven to suicide by corporate corruption, as at Enron and again at Theranos, “The Crime of the Century” is filled with regular people who killed themselves accidentally because they got hooked on a class of painkillers that was marketed as having a low risk of addiction.

No, really, it was. OxyContin, originally approved to treat excruciating “breakthrough” pain in cancer patients, came packaged with instructions that said, “Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug.” There was no evidence to support this language, but it was nonetheless approved — maybe even written — by an FDA administrator named Curtis Wright, who later went to work for Purdue.

The runaway success of a ravenous wolf in FDA-approved sheep’s clothing inspired copycats in the pharmaceutical industry, including an even stronger treatment for breakthrough cancer pain, Subsys. It was manufactured by Insys Therapeutics, whose founder and chairman, John Kapoor, is spending his late 70s in federal prison for bribing doctors to prescribe and persuade other doctors to prescribe Subsys for off-label uses — and to mislead insurance carriers about the diagnoses of the patients.

There was another federal agency that had the authority to crack down on the flow of scheduled pharmaceuticals: the Drug Enforcement Administration. So the industry found some receptive members of Congress — led by Tennessee Rep. Marsha Blackburn and Pennsylvania Rep. Tom Marino — to push through legislation that made it virtually impossible for the DEA to intervene. Blackburn has since moved on to the U.S. Senate, and Marino, naturally, became the head of the DEA in the Trump administration.

Arkansas Rep. French Hill has a presumably unwelcome cameo in “The Crime of the Century.” In 2016, he presided over the bipartisan voice vote by which the House told the DEA to stand down and let the opioids flow. The Senate and President Obama agreed, and the stack of dead bodies continues to accumulate at a pace that, with the exception of 2018, continues to accelerate.

Finally, late last year, Purdue Pharma pleaded guilty to criminal conspiracy charges and agreed to pay $8.3 billion from the profits generated from the death and misery it unleashed. “But,” as The New York Times reported, “it is unlikely the company will pay anything close to the $8.3 billion negotiated in the settlement deal. That is because Purdue sought bankruptcy court protection amid the onslaught of lawsuits, and so the federal government will now have to take its place in a long line of creditors.”

Gwen Moritz is the editor of Arkansas Business.

Originally Appeared Here

Filed Under: BUSINESS

Primary Sidebar

More to See

N.J. town votes to let redevelopment of former Lord & Taylor site move forward

The Westfield Town Council voted 7-1 on Tuesday to introduce an ordinance that allows for a downtown redevelopment plan to move forward.It will next … [Read More...] about N.J. town votes to let redevelopment of former Lord & Taylor site move forward

Bed Bath and Beyond is closing 87 more stores. See the list

New York CNN  —  Bed Bath and Beyond is closing another 87 stores as the struggling retailer barrels toward bankruptcy. … [Read More...] about Bed Bath and Beyond is closing 87 more stores. See the list

U.S. launches high-level defense and tech initiative with India

Comment on this storyCommentThe United States and India on Tuesday formally established a high-level initiative on defense and emerging technologies — … [Read More...] about U.S. launches high-level defense and tech initiative with India

Privacy Policy | Terms and Conditions | About/ Contact
Copyright © 2023 · PRESSLED · As Amazon Associates we earn commissions from qualifying purchases · Log in

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT